Increase in transglutaminase 2 in idiopathic inflammatory myopathies

Youngchul Choi, Tai Seung Kim, Soo Youl Kim

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Idiopathic inflammatory myopathies (IMs), including dermatomyositis (DM), polymyositis (PM), and sporadic inclusion body myositis (s-IBM), are characterized by inflammatory cell infiltration in muscle tissue and muscle fiber destruction, which leads to muscle weakness. Although the cause of IMs is unclear, an autoimmune pathogenesis may be involved in initiating the muscle inflammation. Recently, we have found an aberrant expression of transglutaminase 2 (TGase 2) in s-IBM, which is closely associated with insoluble inclusion body formation. TGase 2 is a cross-linking enzyme that generates a conformational change of molecules via a covalent isopeptide bond. The increase in the level of TGase 2 expression and the inappropriate presentation of substrates/cross-linked aggregates to the immune system may contribute to the autoimmune aspects of IMs. We investigated whether or not an increase in TGase 2 expression is a common factor in muscle inflammation. Duchenne muscular dystrophy (DMD) and normal tissues were employed as controls. Using immunocytochemistry and quantitative RT-PCR, the level of TGase 2 expression was found to be specifically increased in PM and DM, but not in DMD and normal controls. Therefore, the targeting of TGase inhibition in IMs will be a challenging therapeutic approach that should be investigated in the near future.

Original languageEnglish
Pages (from-to)10-14
Number of pages5
JournalEuropean Neurology
Volume51
Issue number1
DOIs
Publication statusPublished - 2004 Jan 14

Fingerprint

Myositis
Inclusion Body Myositis
Muscles
Dermatomyositis
Duchenne Muscular Dystrophy
Inflammation
Inclusion Bodies
Muscle Weakness
Immune System
Immunohistochemistry
transglutaminase 2
Polymerase Chain Reaction
Enzymes

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Choi, Youngchul ; Kim, Tai Seung ; Kim, Soo Youl. / Increase in transglutaminase 2 in idiopathic inflammatory myopathies. In: European Neurology. 2004 ; Vol. 51, No. 1. pp. 10-14.
@article{354dce86d5d54b9cb6b77cbc1ec9f438,
title = "Increase in transglutaminase 2 in idiopathic inflammatory myopathies",
abstract = "Idiopathic inflammatory myopathies (IMs), including dermatomyositis (DM), polymyositis (PM), and sporadic inclusion body myositis (s-IBM), are characterized by inflammatory cell infiltration in muscle tissue and muscle fiber destruction, which leads to muscle weakness. Although the cause of IMs is unclear, an autoimmune pathogenesis may be involved in initiating the muscle inflammation. Recently, we have found an aberrant expression of transglutaminase 2 (TGase 2) in s-IBM, which is closely associated with insoluble inclusion body formation. TGase 2 is a cross-linking enzyme that generates a conformational change of molecules via a covalent isopeptide bond. The increase in the level of TGase 2 expression and the inappropriate presentation of substrates/cross-linked aggregates to the immune system may contribute to the autoimmune aspects of IMs. We investigated whether or not an increase in TGase 2 expression is a common factor in muscle inflammation. Duchenne muscular dystrophy (DMD) and normal tissues were employed as controls. Using immunocytochemistry and quantitative RT-PCR, the level of TGase 2 expression was found to be specifically increased in PM and DM, but not in DMD and normal controls. Therefore, the targeting of TGase inhibition in IMs will be a challenging therapeutic approach that should be investigated in the near future.",
author = "Youngchul Choi and Kim, {Tai Seung} and Kim, {Soo Youl}",
year = "2004",
month = "1",
day = "14",
doi = "10.1159/000074911",
language = "English",
volume = "51",
pages = "10--14",
journal = "European Neurology",
issn = "0014-3022",
publisher = "S. Karger AG",
number = "1",

}

Increase in transglutaminase 2 in idiopathic inflammatory myopathies. / Choi, Youngchul; Kim, Tai Seung; Kim, Soo Youl.

In: European Neurology, Vol. 51, No. 1, 14.01.2004, p. 10-14.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Increase in transglutaminase 2 in idiopathic inflammatory myopathies

AU - Choi, Youngchul

AU - Kim, Tai Seung

AU - Kim, Soo Youl

PY - 2004/1/14

Y1 - 2004/1/14

N2 - Idiopathic inflammatory myopathies (IMs), including dermatomyositis (DM), polymyositis (PM), and sporadic inclusion body myositis (s-IBM), are characterized by inflammatory cell infiltration in muscle tissue and muscle fiber destruction, which leads to muscle weakness. Although the cause of IMs is unclear, an autoimmune pathogenesis may be involved in initiating the muscle inflammation. Recently, we have found an aberrant expression of transglutaminase 2 (TGase 2) in s-IBM, which is closely associated with insoluble inclusion body formation. TGase 2 is a cross-linking enzyme that generates a conformational change of molecules via a covalent isopeptide bond. The increase in the level of TGase 2 expression and the inappropriate presentation of substrates/cross-linked aggregates to the immune system may contribute to the autoimmune aspects of IMs. We investigated whether or not an increase in TGase 2 expression is a common factor in muscle inflammation. Duchenne muscular dystrophy (DMD) and normal tissues were employed as controls. Using immunocytochemistry and quantitative RT-PCR, the level of TGase 2 expression was found to be specifically increased in PM and DM, but not in DMD and normal controls. Therefore, the targeting of TGase inhibition in IMs will be a challenging therapeutic approach that should be investigated in the near future.

AB - Idiopathic inflammatory myopathies (IMs), including dermatomyositis (DM), polymyositis (PM), and sporadic inclusion body myositis (s-IBM), are characterized by inflammatory cell infiltration in muscle tissue and muscle fiber destruction, which leads to muscle weakness. Although the cause of IMs is unclear, an autoimmune pathogenesis may be involved in initiating the muscle inflammation. Recently, we have found an aberrant expression of transglutaminase 2 (TGase 2) in s-IBM, which is closely associated with insoluble inclusion body formation. TGase 2 is a cross-linking enzyme that generates a conformational change of molecules via a covalent isopeptide bond. The increase in the level of TGase 2 expression and the inappropriate presentation of substrates/cross-linked aggregates to the immune system may contribute to the autoimmune aspects of IMs. We investigated whether or not an increase in TGase 2 expression is a common factor in muscle inflammation. Duchenne muscular dystrophy (DMD) and normal tissues were employed as controls. Using immunocytochemistry and quantitative RT-PCR, the level of TGase 2 expression was found to be specifically increased in PM and DM, but not in DMD and normal controls. Therefore, the targeting of TGase inhibition in IMs will be a challenging therapeutic approach that should be investigated in the near future.

UR - http://www.scopus.com/inward/record.url?scp=0347416645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347416645&partnerID=8YFLogxK

U2 - 10.1159/000074911

DO - 10.1159/000074911

M3 - Article

C2 - 14631123

AN - SCOPUS:0347416645

VL - 51

SP - 10

EP - 14

JO - European Neurology

JF - European Neurology

SN - 0014-3022

IS - 1

ER -